APA (7th ed.) Citation

Zhang, Y., Numata, K., Imajo, K., Uojima, H., Funaoka, A., Komiyama, S., . . . Iwase, S. (2024). Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study. Hepatology Research, 54(12), 1174. https://doi.org/10.1111/hepr.14089

Chicago Style (17th ed.) Citation

Zhang, Ying, et al. "Lenvatinib Radiofrequency Ablation Sequential Therapy Offers Survival Benefits for Patients with Unresectable Hepatocellular Carcinoma at Intermediate Stage and the Liver Reserve of Child–Pugh A Category: A multicenter Study." Hepatology Research 54, no. 12 (2024): 1174. https://doi.org/10.1111/hepr.14089.

MLA (9th ed.) Citation

Zhang, Ying, et al. "Lenvatinib Radiofrequency Ablation Sequential Therapy Offers Survival Benefits for Patients with Unresectable Hepatocellular Carcinoma at Intermediate Stage and the Liver Reserve of Child–Pugh A Category: A multicenter Study." Hepatology Research, vol. 54, no. 12, 2024, p. 1174, https://doi.org/10.1111/hepr.14089.